Minerva Pb Ratio vs Price To Sales Ratio Analysis

NERV Stock  USD 2.26  0.00  0.00%   
Minerva Neurosciences financial indicator trend analysis is infinitely more than just investigating Minerva Neurosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Minerva Neurosciences is a good investment. Please check the relationship between Minerva Neurosciences Pb Ratio and its Price To Sales Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Minerva Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.

Pb Ratio vs Price To Sales Ratio

Pb Ratio vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Minerva Neurosciences Pb Ratio account and Price To Sales Ratio. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Minerva Neurosciences' Pb Ratio and Price To Sales Ratio is 0.19. Overlapping area represents the amount of variation of Pb Ratio that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Minerva Neurosciences, assuming nothing else is changed. The correlation between historical values of Minerva Neurosciences' Pb Ratio and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pb Ratio of Minerva Neurosciences are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Pb Ratio i.e., Minerva Neurosciences' Pb Ratio and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.19
Relationship DirectionPositive 
Relationship StrengthInsignificant

Pb Ratio

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Minerva Neurosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Minerva Neurosciences sales, a figure that is much harder to manipulate than other Minerva Neurosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.
Most indicators from Minerva Neurosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Minerva Neurosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Minerva Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.At this time, Minerva Neurosciences' Selling General Administrative is fairly stable compared to the past year. Tax Provision is expected to grow at the current pace this year, whereas Enterprise Value Over EBITDA is likely to drop (3.93) in 2024.
 2023 2024 (projected)
Extraordinary Items8.5M7.5M
Reconciled Depreciation29.6K57.8K

Minerva Neurosciences fundamental ratios Correlations

-0.470.810.76-0.55-0.340.650.960.650.460.040.620.480.960.70.040.180.720.630.630.020.750.690.360.170.36
-0.47-0.48-0.40.00.110.06-0.5-0.27-0.24-0.68-0.28-0.24-0.5-0.440.25-0.7-0.24-0.45-0.280.16-0.28-0.2-0.18-0.710.1
0.81-0.480.66-0.6-0.260.630.730.550.340.320.490.310.730.65-0.050.370.670.650.590.050.710.650.160.390.01
0.76-0.40.66-0.380.260.310.670.2-0.04-0.020.14-0.10.660.7-0.580.140.330.190.88-0.490.880.24-0.230.150.33
-0.550.0-0.6-0.380.29-0.75-0.56-0.45-0.370.0-0.42-0.25-0.55-0.59-0.14-0.09-0.45-0.6-0.25-0.26-0.35-0.47-0.17-0.02-0.28
-0.340.11-0.260.260.29-0.57-0.41-0.87-0.91-0.19-0.91-0.82-0.42-0.28-0.78-0.3-0.73-0.70.41-0.550.14-0.79-0.8-0.27-0.05
0.650.060.630.31-0.75-0.570.680.730.63-0.070.70.590.690.540.420.010.70.640.10.160.330.690.51-0.050.26
0.96-0.50.730.67-0.56-0.410.680.680.580.040.660.571.00.670.130.150.660.670.470.050.590.640.480.130.35
0.65-0.270.550.2-0.45-0.870.730.680.920.190.990.810.690.610.50.370.910.79-0.050.270.270.910.740.330.18
0.46-0.240.34-0.04-0.37-0.910.630.580.920.170.940.830.590.420.60.290.70.76-0.310.42-0.050.730.80.260.17
0.04-0.680.32-0.020.0-0.19-0.070.040.190.170.210.150.040.31-0.180.920.160.52-0.05-0.110.020.140.110.93-0.07
0.62-0.280.490.14-0.42-0.910.70.660.990.940.210.820.670.590.540.390.880.79-0.10.30.20.890.750.350.19
0.48-0.240.31-0.1-0.25-0.820.590.570.810.830.150.820.580.230.730.160.710.74-0.270.410.00.730.990.110.14
0.96-0.50.730.66-0.55-0.420.691.00.690.590.040.670.580.670.150.150.670.670.470.050.580.650.490.130.35
0.7-0.440.650.7-0.59-0.280.540.670.610.420.310.590.230.67-0.220.570.630.630.43-0.350.620.540.120.480.29
0.040.25-0.05-0.58-0.14-0.780.420.130.50.6-0.180.540.730.15-0.22-0.210.40.35-0.590.7-0.430.50.78-0.25-0.18
0.18-0.70.370.14-0.09-0.30.010.150.370.290.920.390.160.150.57-0.210.350.560.03-0.190.160.30.10.98-0.04
0.72-0.240.670.33-0.45-0.730.70.660.910.70.160.880.710.670.630.40.350.740.230.210.540.990.60.330.16
0.63-0.450.650.19-0.6-0.70.640.670.790.760.520.790.740.670.630.350.560.740.050.30.270.750.670.510.27
0.63-0.280.590.88-0.250.410.10.47-0.05-0.31-0.05-0.1-0.270.470.43-0.590.030.230.05-0.340.930.17-0.380.080.33
0.020.160.05-0.49-0.26-0.550.160.050.270.42-0.110.30.410.05-0.350.7-0.190.210.3-0.34-0.330.370.44-0.13-0.11
0.75-0.280.710.88-0.350.140.330.590.27-0.050.020.20.00.580.62-0.430.160.540.270.93-0.330.46-0.130.190.36
0.69-0.20.650.24-0.47-0.790.690.640.910.730.140.890.730.650.540.50.30.990.750.170.370.460.640.290.14
0.36-0.180.16-0.23-0.17-0.80.510.480.740.80.110.750.990.490.120.780.10.60.67-0.380.44-0.130.640.050.14
0.17-0.710.390.15-0.02-0.27-0.050.130.330.260.930.350.110.130.48-0.250.980.330.510.08-0.130.190.290.05-0.03
0.360.10.010.33-0.28-0.050.260.350.180.17-0.070.190.140.350.29-0.18-0.040.160.270.33-0.110.360.140.14-0.03
Click cells to compare fundamentals

Minerva Neurosciences Account Relationship Matchups

Minerva Neurosciences fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets77.5M57.6M77.1M55.1M56.9M88.0M
Other Current Liab(41.2B)2.1M965.7K407.9K1.5M1.6M
Total Current Liabilities6.6M3.2M2.8M1.4M3.3M4.4M
Total Stockholder Equity27.8M52.7M8.0M(20.0M)(28.5M)(27.0M)
Net Debt(21.1M)(25.2M)(60.8M)37.6M(40.9M)(38.9M)
Retained Earnings(286.7M)(284.8M)(334.7M)(366.8M)(396.8M)(377.0M)
Cash21.4M25.4M60.8M36.1M40.9M34.7M
Cash And Short Term Investments45.9M25.4M60.8M36.1M41.0M51.4M
Common Stock Total Equity3.9K3.9K3.9K4.3K4.9K3.0K
Common Stock Shares Outstanding4.9M5.1M5.3M5.3M6.5M4.6M
Liabilities And Stockholders Equity77.5M57.6M77.1M55.1M56.9M88.0M
Other Current Assets1.3B2.1M1.4M848.1K1.1M1.0M
Other Stockholder Equity314.5M337.5M342.7M346.8M368.4M264.5M
Total Liab49.7M5.0M69.1M75.1M85.4M42.7M
Total Current Assets47.1M27.4M62.2M40.2M42.0M52.9M
Common Stock3.9K4K4.3K534.0699.0664.05
Property Plant And Equipment Net278K101.8K51.1K16.3K10.9K10.3K
Accounts Payable2.3M995.6K1.9M969.7K1.8M1.5M
Non Current Assets Total30.4M30.2M14.9M14.9M14.9M27.9M
Non Current Liabilities Total43.1M1.8M66.3M73.7M82.0M41.8M
Property Plant And Equipment Gross278.0K101.8K0.016.3K18.8K17.8K
Short Term Debt4.0M41.2B173K111.2K127.9K121.5K
Property Plant Equipment33.5K16.0K101.8K16.3K18.8K36.8K
Other Liab43.0M1.8M66.3M73.7M84.8M89.0M
Net Tangible Assets(2.3M)22.6M(6.9M)(34.9M)(31.4M)(29.9M)
Retained Earnings Total Equity(164.4M)(214.6M)(286.7M)(284.8M)(256.3M)(269.1M)
Short Term Investments102.1M37.8M24.4M100K90K85.5K
Capital Surpluse296.0M304.8M314.5M337.5M388.1M278.9M
Non Current Liabilities Other41.2M41.3M66.3M73.7M82.0M41.9M
Net Invested Capital27.8M52.7M8.0M(20.0M)(28.5M)(27.0M)
Net Working Capital40.5M24.3M59.4M38.8M38.7M46.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Minerva Stock Analysis

When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.